Novo Nordisk (NVO) made a higher offer for Metsera in an effort to beat an agreed deal with Pfizer (PFE) and to cosolidate its position in weight-loss medications, Josh Sisco, David Carnevali, Aaron Kirchfeld, and Dinesh Nair of Bloomberg reports, citing people with knowledge of the matter. Metsera and Novo Nordisk are in advanced discussions on the new bid and could reach an agreement by Thursday, the sources said.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Eli Lilly, Novo Nordisk weight loss drugs deemed cost effective by ICER
- New Walmart and Eli Lilly Partnership Puts Weight Loss Drugs on the Shopping List
- Mixed options sentiment in Novo Nordisk with shares down 1.59%
- Novo Nordisk’s New Study on Haemophilia: What Investors Need to Know
- Novo Nordisk’s New Study on Cagrilintide: A Potential Game-Changer in Weight Management